ライフサイエンスコーパス: phase I

1 nts had dose-limiting toxicities in cycle 1 (phase I).

2 l limbic/paralimbic and neocortical regions (phase I).

3 ntal and parietal regions, as early as acute phase I.

4 ate that water dynamics in the normal gyroid phase is 1 order of magnitude slower than that in bulk w

5 Two trials, phase I (1987 to 1990), over 18 months, and phase II (19

6 olling structure and properties of the C-S-H phase is a challenge, due to the complexity of this hydr

7 olated and cold molecular complex in the gas-phase is a fundamental measure of the strength of the in

8 The charge-density-wave (CDW) phase is a macroscopic quantum state consisting of a per

9 phization of dc-Si via an intermediate dh-Si phase is a previously unknown pathway of solid-state amo

10 The self-organizing fast phase is a result of viscous drag on kinesin-driven carg

11 d hcp high-entropy alloy reveal that the fcc phase is a stable polymorph at high temperatures, while

12 The observed frustrated phase is a template for similar ordering in other liquid

13 d liquid-crystalline phases, like cubic blue phases, is a formidable task.

14 Haplotype phasing is a fundamental problem in medical and populati

15 DNA replication during S phase is accompanied by establishment of sister chromati

16 It therefore remains unexplained why the lag-phase is adaptive.

17 of polyphosphate observed at the stationary phase is added to cells at mid-log, proliferation is hal

18 The compositional range of the icosahedral phase is Al68-73Fe11-16Cu10-12Cr1-4Ni1-2 and extends tow

19 rs even for the 85Al alloy where the primary phase is alpha-Al.

20 Circadian phase is also advanced under temperature cycles, but a l

21 This phase is an electride, with electron pairs localized in

22 The quantum spin Hall (QSH) phase is an exotic phenomena in condensed-matter physics

23 organic-in-water emulsion, where the organic phase is an ionic liquid [P6,6,6,14][FAP]/toluene mixtur

24 uggest that stacking disorder and mixture of phases is an effective mechanism to modify the anisotrop

25 Haplotype phasing is an important problem in the analysis of genom

26 Among 744 phase I and 2,382 phase II participants randomized to so

27 Results We treated 49 patients in phase I and 44 patients in phase II.

28 Developmental effects of the ToxCast Phase I and II chemicals in Caenorhabditis elegans and c

29 Accordingly, Dex-based phase I and II clinical trials have been conducted in ad

30 However, phase I and II clinical trials with autologous and first

31 ly, while application of oxidative stress to phase I and II iron-limited cells similarly oxidized the

32 Results from phase I and II studies have shown relatively stable and

33 g from preclinical studies to the designs of phase I and IIa clinical trials involving direct intrasp

34 Across both the Phase I and Phase II libraries, 62% of the chemicals wer

35 onmental Protection Agency's (EPA's) ToxCast Phase I and Phase II libraries, which contain 292 and 67

36 Flavonoids are extensively metabolized by phase I and phase II metabolism (which occur predominant

37 Different phase I and phase II metabolites of the pesticides were

38 tory criteria, suggesting that comparison of phase I and phase II titers could be reexamined as a sur

39 metry we identified 33 AMI metabolites (both Phase I and Phase II), occurring mostly in bile, liver a

40 Further 10 TPs (phase-I and II) were identified by LC-high resolution ma

41 Patients were examined at 2 to 3 days (acute phase I) and 8 to 10 days (acute phase II), and some of

42 fined two distinct phases: short-term (<3 d, phase I) and chronic (>5 d, phase II) iron limitation.

43 ry end points were maximum-tolerated dosage (phase I) and complete remission rate within the first tw

44 TRX1 inhibition via shRNA or a phase I-approved inhibitor, PX-12 (untested in prostate

45 Its acute phase is associated with high parasitism, myocarditis an

46 Usually, the exciton phase is associated with low temperatures.

47 ural characterization of proteins in the gas phase is becoming increasingly popular, highlighting the

48 phase II and III trials citing the original phase I biomarker studies to determine the impact on dru

49 t has been proposed that the superconducting phase is body-centered cubic H3 S (Im3 m, a=3.089 A) res

50 T cells signal during transient contacts of phase I, but this has never been shown directly.

51 3/KHCO3 in the lower phase, HEP in the upper phase is capable of being regenerated from its sulfite/s

52 activate from latency and re-enter the lytic phase is challenging to investigate and control, it is k

53 scattering studies reveal that this complex phase is characterized by a gigantic tetragonal unit cel

54 Accordingly, each phase is characterized by a specific pattern of gene exp

55 pen-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and s

56 en C. elegans and one zebrafish assay across Phase I chemicals (79%) than with a second zebrafish ass

57 The supramolecular phase is clearly distinguished from the polymeric one us

58 ave been incorporated into an ADC that is in phase I clinical development.

59 The human PK properties from the Phase I clinical studies of 37 were better than anticipa

60 safety and immunogenicity in multiple HIV-1 phase I clinical studies.

61 166, which is currently being evaluated in a phase I clinical study.

62 TING agonists are being carried forward into phase I clinical testing.

63 , which is currently being investigated in a phase I clinical trial (NCT02237638), can potentially ou

64 Conclusion: This first-in-human, phase I clinical trial demonstrates the safe use and cli

65 This first-in-human, phase I clinical trial demonstrates the safe use and cli

66 s Administration (TGA) prior to conducting a Phase I clinical trial evaluating the safety and tolerab

67 CX-5461 is now in advanced phase I clinical trial for patients with BRCA1/2 deficie

68 vivo in preclinical animal models, and in a phase I clinical trial in patients with advanced cancers

69 s sequentially, enabling the use of existing phase I clinical trial toxicity data.

70 ministering 1 to healthy human volunteers, a phase I clinical trial was conducted.

71 The aim of this first-in-human, phase I clinical trial was to investigate the safety and

72 AZD9496 is currently being evaluated in a phase I clinical trial.

73 ions in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabi

74 Patients with advanced sarcoma treated on phase I clinical trials had a clinical benefit rate of 3

75 as a clinical candidate for advancement into phase I clinical trials to assess safety and tolerabilit

76 cleotide-based therapies have been tested in phase I clinical trials, a quarter of which have reached

77 n dosed at 160 mg/kg BID and is currently in Phase I clinical trials.

78 s (NYVAC-C) showed limited immunogenicity in phase I clinical trials.

79 bromodomain inhibitor that recently entered phase I clinical trials.

80 ETi at effective doses have been reported in phase I clinical trials.

81 Interestingly, this precursor phase is co-aligned with the c-axes of the mature bone c

82 The mixing of the organic and aqueous phases is confined under a quasi-2D geometry.

83 Phase-I conversion of six Cys residues to thiazoles (Tcl

84 the sigma phase grows directly when the BCC phase is cooled below TOOT and vice versa upon heating.

85 which the transition through mitosis and G1 phase is crucial for establishing a window of opportunit

86 ingredient for the emergence of topological phases, is currently drawing considerable interest.

87 On the basis of the phase I data, the recommended blinatumomab dosage for ch

88 The second phase is dedicated to the assembly of [4Fe-4S] proteins,

89 The second phase is dependent on the activation of the chloroplast

90 of single-crystalline ReS2 in a distorted 1T phase is determined at room temperature for the in-plane

91 ndings do not support the concepts that this phase is devoid of markers of disease progression or tha

92 We discover that the nature of the new phase is dictated by the stacking order, and our results

93 ntial, and the perspective of building novel phases is directly linked to the control of tuning param

94 rs old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, usin

95 We conducted a phase I dose escalation study in which 9 patients with r

96 Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with

97 We conducted a phase I dose-escalation study with (89)Zr-desferrioxamin

98 We undertook a phase I double-blind, randomized placebo controlled tria

99 We show that this QAH phase is driven by a single inversion in the band struct

100 me P450s are the primary enzymes involved in phase I drug metabolism.

101 is generally accompanied by formation of new phases (i.e. LnAlO3, Ln2O3), and therefore inclusion of

102 wer orientation were carried out to identify phases (i.e. the timing of peaks) by subdividing time se

103 sition between the two structurally distinct phases (i.e., brownmillerite and perovskite) is quantita

104 al distributions of electrochemically active phases (i.e., compositional inhomogeneity).

105 However, the fates of the diverse carbonate phases (i.e., mineral and amorphous forms of CaCO3) they

106 netics (IEK) performed on typical Ni bearing phases (i.e., two types of serpentines, chlorite, smecti

107 reversibly transit between the two distinct phases, i.e. the brownmillerite SrCoO2.5 that is a room-

108 The primary phase I end point was the maximum tolerated dose of TMZ.

109 irreversible transition from interphase to M phase is essential to separate DNA replication from chro

110 ent of DMS chemistry in both gas and aqueous phases is essential to improve the accuracy of model pre

111 onless transformation from beta to alpha (') phase is evident.

112 Purpose This phase I expansion cohort study evaluated the safety and

113 high pressures and temperatures, where the A-phase is favoured.

114 trast-enhanced examination and hepatobiliary phase is feasible and time-saving.

115 A confined phase is first seen to form along the apex of the wedge

116 how, unambiguously, that a smectic-A type of phase is formed by increasing the DNA's flexibility thro

117 sformation pathways and explains why the new phase is found in an annular region.

118 Furthermore, the cubic phase is found to be the energetically favored polytype.

119 This phase is found to coexist with the nominal orthorhombic

120 se, while wall position in the other cardiac phases is found by image registration.

121 uest for universal properties of topological phases is fundamentally important because these signatur

122 Phasing is generally performed via statistical phasing i

123 make excellent frameworks for salt-inclusion phases is given.

124 Distinguishing single-Q and multi-Q magnetic phases is however a notoriously difficult experimental p

125 The formative phase is hypothesised to be enabling for the execution o

126 e for new treatment development, where early phases (I, I/II) are designed to test safety and effecti

127 The cg-PN phase is identified by Raman and attenuated total reflec

128 ive safety review on data from three trials (phase I, II, and III) included patients with advanced me

129 aride conjugate vaccines have been tested in phase I/II clinical studies, showing promise for further

130 d spinal cord embedded into state-of-the-art Phase I/II clinical trial design studies for human SCI.

131 SAFE-MILND (NCT01500304) is a multicenter, phase I/II clinical trial evaluating the safety and feas

132 Entrectinib is currently undergoing phase I/II clinical trial for the treatment of patients

133 vivo in preclinical animal models, and in a phase I/II clinical trial in patients with advanced canc

134 tic lymphoma kinase (ALK), and is undergoing Phase I/II clinical trial investigations for non-small c

135 This phase I/II clinical trial represents a novel experience

136 nt preclinical testing to proceed to a pilot phase I/II clinical trial.

137 b), a dual PI3K/mTOR inhibitor that is under phase I/II clinical trials for the treatment of some typ

138 the groundwork for its current evaluation in phase I/II clinical trials in patients harboring EGFR mu

139 high translational potential, given current phase I/II clinical trials with alpha-4-1BB against vari

140 h pre-clinical models and in patients during phase I/II clinical trials.

141 ciple with the publication of a first-in-man phase I/II dose escalation clinical trial in patients wi

142 We report interim data from a phase I/II dose-escalation/expansion study of NEOD001 in

143 Phase I/II studies in human immunodeficiency virus (HIV)

144 t the results of the phase II component of a phase I/II study that evaluated the sensitivity of (68)G

145 We performed a prospective phase I/II study to evaluate the sst receptor antagonist

146 ples, yielded consistent results with recent phase I/II trials, suggesting that EMMA is a feasible pl

147 igenetic changes for cancer treatment are in Phase I/II trials; however, all of these target only nuc

148 We performed a randomized Phase I/II, observer-blind, placebo-controlled study of

149 We report the results of a phase I/II, open-label, single-arm clinical trial to eva

150 Phase I/II, prospective, 24-month, dose-ranging, paired-

151 ntigen receptor-modified T cell therapy on a phase I/IIa clinical trial.

152 wed good clinical tolerability in a previous phase I/IIa clinical trial.

153 pancreatic cancer mechanisms and conducted a phase I/IIa study to investigate pharmacokinetic interac

154 ration and is currently being evaluated in a phase I/IIa study.

155 Eight patients with endocarditis had phase I immunoglobulin G antibody titers >800 but did no

156 Understanding factors determining this lag phase is important for drug development.

157 Cooling molecules in the gas phase is important for precision spectroscopy, cold mole

158 al superconductors and their superconducting phase is important for understanding the complex physics

159 Understanding the properties of this phase is important to clarify the amorphization and crys

160 response (HVR) is biphasic, consisting of a phase I increase in ventilation followed by a secondary

161 n acidification, GlcCer solubility in the lo phase is increased, leading to a larger lo/ld coexistenc

162 lls, suggesting that the preference for S/G2 phase is independent of the nature of the viral genome.

163 In rice (Oryza sativa), the reproductive phase is initiated by exposure to short days when expres

164 The termination phase is initiated by PDEs actively targeting the protei

165 gest that the melting of the cubic rock-salt phases is initiated at the vacancies, which propagate to

166 This new phase is intrinsically phase separated into insulating d

167 on of shelterin component Ccq1 during late S phase is involved in telomerase recruitment through prom

168 tained below -10 degrees C, whereas the beta-phase is isolated when the substrate temperature is main

169 ly of the replication fork helicase during S phase is key to the initiation of DNA replication in euk

170 rowth of a quasicrystal from a parent liquid phase is lacking.

171 This unidentified phase is located at the interface between the mature bon

172 anonical H3.1 protein, incorporated during S-phase, is maintained at high levels in cells dividing at

173 file, the lead compound 10a was evaluated in phase I metabolic stability studies in mouse liver micro

174 rlier in TiO2 photocatalysis and in in vitro phase I metabolism assays performed using human liver mi

175 space of structures with a high risk of AOX phase I metabolism in humans.

176 ity of the method was examined for mimicking phase I metabolism reactions of amodiaquine, buspirone a

177 ite, it has been reported that several major phase I metabolites of SCs remain biologically active, e

178 sks by correctly predicting elution order of Phase I metabolites, including isomeric monohydroxylated

179 B-CHMINACA and ADB-CHMINACA) and their major phase I metabolites.

180 and 5F-PB-22, respectively), and their main phase I metabolites.

181 s spectrometry to quantify methylone and its phase I metabolites: 3,4-methylenedioxycathinone (MDC),

182 on both embryotoxicity and mRNA induction of phase I metabolizing enzymes (CYP1A4/5).

183 K higher because the ferromagnetic metallic phase is more dominant at all temperatures below the Cur

184 e morphology suggests that the hydrogen-rich phase is more similar to a spherical cap on the hydrogen

185 ations also indicate that the small bcc CuZn phase is more stable against Cu adatom migration than th

186 e activation volume of the antiferromagnetic phase is more than two orders of magnitude larger than t

187 umab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial.

188 ed that virulent Coxiella burnetii Nine Mile phase I (NMI) is capable of infecting and replicating wi

189 While at phase I no significant changes in physiological paramete

190 Materials and Methods This was a prospective phase I nonrandomized study conducted between March 2013

191 network of pores filled with the nonwetting phase is not necessarily connected.

192 ver the structural influence of Zn on the Cu phase is not well studied.

193 The Berry phase is observed and measured by direct imaging of the

194 In the Y2O3 layer, the original cubic phase is observed to transform to the monoclinic phase a

195 H and cesium concentrations in the receiving phase is observed when receptor 2 is employed as a carri

196 Here, we report the results of phase I of the study.

197 n patients (one ineligible) were enrolled in phase I of the study.

198 Here in phase I of this study, we perform exome sequencing on ba

199 etic separation to superconducting inorganic phases is of particular interest in combination with cer

200 an the mass transfer through respective bulk phases is of specific interest when tracking the transie

201 We identified 4,840 phase I oncology publications between 2003 and 2010.

202 elopment through a comprehensive analysis of phase I oncology studies from 2003 to 2010 and subsequen

203 arch to identify and examine publications of phase I oncology studies including the use of biopsy-der

204 biopsy-derived pharmacodynamic biomarkers in phase I oncology studies on subsequent drug development

205 e science of packing columns with stationary phases is one of the most crucial steps to achieve consi

206 In this phase I, open-label, dose-escalation, cohort-expansion s

207 ical studies, but many have failed either in phase I or II and none has progressed beyond phase II.

208 nobiotic resistance (MXR) or detoxification (phases I or II).

209 The new phase is particularly attractive for molecular separatio

210 etamagnetism occuring inside a ferromagnetic phase is peculiar.

211 g molecules and their metabolites in the gas phase is poorly understood.

212 raj et al demonstrated single individual SNV phasing is possible with proximity ligated (HiC) sequenc

213 confinement and a spatially modulated stripe phase is predicted at the A-B phase boundary.

214 tinization environments where a separate gas phase is present may be more favorable for abiotic synth

215 tructure of the low-temperature orthorhombic phase is preserved.

216 central black hole, and show that the prompt phase is produced via fast-cooling synchrotron radiation

217 ional nanodroplets dispersed in a continuous phase is proposed.

218 In this Phase I randomised controlled clinical trial in HIV-1 ne

219 We conducted a phase I, randomized, double-blind, placebo-controlled, d

220 Presently, the phase is reconstructed by iterative algorithms, imposing

221 The first phase is related predominantly to the reach location, an

222 The stability of the 9R phase is related to the existence of sessile Frank loops

223 hase and a high-resistance crystalline gamma phase is reported for the first time.

224 during HR in G2 phase, and its absence in S phase is required for replication fork stability.

225 The associated reperfusion phase is responsible for the activation of the innate an

226 iour of CrMnFeCoNi is unique in that the hcp phase is retained following decompression to ambient pre

227 LM11A-31 has successfully completed Phase I safety and pharmacokinetic clinical trials and i

228 Results show that phase is sensitive to cycle length choice, a limitation

229 we calculated when the gustatory stimulation phase is short or absent.

230 ells of these mutants, likely because the G1 phase is shorter and a new bud site is established prior

231 ciples calculations, this exact model of QSH phase is shown to be realizable in an experimental syste

232 This state, labelled here the 'harmonic phase', is shown to occur experimentally in spin ice, a

233 In many species the first embryonic M-phase is significantly prolonged compared to the subsequ

234 he behavior of the foldamers in the membrane phase is similar to that of analogous compounds in organ

235 macokinetic data (280 venous samples) from a phase I single (50 mg) dose study in healthy older peopl

236 onatomic and molecular systems if the liquid phase is slow enough to induce viscoelastic phase separa

237 ct UHS, which works in two phases: The first phase is solved optimally, and for the second we propose

238 tion between the A and B phases, where the A phase is stabilized by confinement and a spatially modul

239 latter, suggesting that a spin-density-wave phase is stabilized in zero field by Nd and Gd impuritie

240 te phase and its relation to the martensitic phase is still an unresolved issue, even though it is cr

241 Based on the observation that the segregated phase is strongly affected by temperature, we propose to

242 ce precipitate, most likely an autunite-like phase, is strongly suggested.

243 of FAPbI3 between the alpha-phase and delta-phase is studied.

244 Two Phase I studies in healthy human subjects evaluated safe

245 A criteria have routinely been enrolled onto phase I studies of antineoplastics without clinically me

246 or currently under investigation in multiple phase I studies on various malignancies, and its clincal

247 py Evaluation Program-sponsored single-agent phase I studies over three decades (1979 to 2010).

248 riguing clinical safety and efficacy data in phase I studies.

249 tion of BAY 1187982 in cancer patients and a phase I study (NCT02368951) has been initiated.

250 In a phase I study of cabozantinib, five of eight patients wi

251 Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxic

252 A phase I study recently reported that seviteronel, a CYP1

253 This phase I study sought to determine the safety and antitum

254 Patients and Methods This phase I study tested durvalumab doublets in parallel 3 +

255 Patients and Methods This phase I study tested the combination of M6620 and topote

256 armacokinetic data derived from our clinical phase I study to set parameter values.

257 The goal of this phase I study was to determine the maximum tolerated dos

258 The aim of the present phase I study was to evaluate the biodistribution and do

259 In a phase I study, the maximum tolerated dose of AZD1775 in

260 ouble-blinded, placebo-controlled, crossover phase I study.

261 in a patient with ACC who was enrolled in a phase I study.

262 mber of photons emitted during the starburst phase is sufficient to ionize intergalactic medium mater

263 alues, the HO phase reenters after the LMAFM phase is suppressed by the magnetic field, similar to th

264 In vivo, we found that during phase I, T cells exhibit weak calcium fluxes and detecta

265 In phase I, T cells make multiple transient contacts with d

266 room temperature at which this orthorhombic phase is the equilibrium state.

267 Strengthening by precipitation of second phase is the guiding principle for the development of a

268 e of viral Ag presentation into the effector phase is the key factor that determines the efficiency o

269 s, whereas below TOOT the Frank-Kasper sigma phase is the stable morphology.

270 terconversion between the two distinct HS-LS phases is the result of subtle structural changes in the

271 The implementation of Target: Stroke Phase I, the first stage of the American Heart Associati

272 eoretically explain its four life phases: In phase I, the spherical cap-shaped droplet remains transp

273 structure, which we designate as smectic-fA phase, is thermodynamically stabilized by both entropic

274 The interplay between such phases is thought to play a critical role in the unconve

275 f polar contaminants with DOM in the aqueous phase is thus a disregarded pathway along which contamin

276 -induced transformations of linear OCS (R3m, Phase I) to bent OCS (Cm, Phase II) at 9 GPa; an amorpho

277 Phase I treatments were anti-VEGF-based (n = 45), mTOR i

278 Purpose This phase I trial evaluated epigenetic modulation of vascula

279 METHODS AND A randomised, open-label phase I trial in Lambarene, Gabon, studied 5 single intr

280 A phase I trial in patients with NHL was conducted to dete

281 in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitoc

282 Receiving cytotoxic chemotherapy as part of phase I trial was also associated with shorter median OS

283 basis of preclinical evidence and a previous phase I trial, respectively.

284 studies demonstrated that in an HIV vaccine phase I trial, the DP6-001 trial, a polyvalent Env DNA p

285 enicity of RG7787 is now being assessed in a phase I trial.

286 ral solid tumor types, and the initiation of phase I trials for A2AR antagonists in oncology, this ap

287 e clinical solution to challenges arising in phase I trials from the dose-dependent side effects of t

288 Approximately 36% of patients enrolled onto phase I trials had mild renal dysfunction by FDA criteri

289 including Roneparstat, a modified heparin in phase I trials in myeloma patients, significantly inhibi

290 The first phase is triggered by rapid light-induced changes in gen

291 initial assembly, or nucleation, of the new phase is typically a highly stochastic process and does

292 e macrophage population associated with each phase is unclear.

293 MI acute inflammatory response and resolving phase is unclear.

294 SVD and the extent of bleeding at the acute phase is unknown to date.

295 The preferred phase is usually zincian malachite.

296 al phases termed "diapause development." The phasing is varied in the literature, and the whole conce

297 its, our present understanding of the active phase is very unsatisfying.

298 tion, in which a component of one of the two phases is vesicles rather than macromolecules, could und

299 g PPARgamma activators identified in ToxCast Phase I were genuine PPARgamma activators and inducers o

300 l of 11 transformation products (TP) (mainly phase-I) were quantified by liquid chromatography-tandem